Provided herein are novel amide prodrug forms of pharmaceutically active agents useful for central nervous system disorders.

Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: ##STR00001##
wherein W, X, Y, Z, x, R.sup.1, R.sup.2, R.sup.3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.

Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: ##STR00001##
wherein W, X, Y, Z, x, R.sup.1, R.sup.2, R.sup.3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.

Substituted aromatic sulfonamides of formula (I)

##STR00001##

pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

Substituted aromatic sulfonamides of formula (I)

##STR00001##

pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

The present disclosure relates to a chemical compound having the general formula (I):

##STR00001##

wherein R.sub.1 is a phenyl group and R.sub.2 is a meta-substituted phenyl group; and R.sub.TA is a substituted or unsubstituted thiazole ring. The disclosure also relates to said compound according to formula (I), in particular in its diastereomerically pure or enriched form, for use in therapy, in particular for treating and/or preventing age-related cognitive decline. Further, the disclosure relates to said compound according to formula (I) for use in improving cognitive functions, in particular for use in improving the spatial learning capabilities in human individuals. And, disclosure also relates to said compound according to formula (I) for use in the treatment and/or prevention of alcohol addiction, nicotine addiction and/or drug addiction, in particular cocaine and/or metamphetamine addiction.

The present disclosure relates to a chemical compound having the general formula (I):

##STR00001##

wherein R.sub.1 is a phenyl group and R.sub.2 is a meta-substituted phenyl group; and R.sub.TA is a substituted or unsubstituted thiazole ring. The disclosure also relates to said compound according to formula (I), in particular in its diastereomerically pure or enriched form, for use in therapy, in particular for treating and/or preventing age-related cognitive decline. Further, the disclosure relates to said compound according to formula (I) for use in improving cognitive functions, in particular for use in improving the spatial learning capabilities in human individuals. And, disclosure also relates to said compound according to formula (I) for use in the treatment and/or prevention of alcohol addiction, nicotine addiction and/or drug addiction, in particular cocaine and/or metamphetamine addiction.

The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such as pain, ADHD/ADD, alcohol use disorder, anxiety disorder, and dementias.

The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such as pain, ADHD/ADD, alcohol use disorder, anxiety disorder, and dementias.

A photo-decomposable compound, a photoresist composition, and a method of manufacturing an IC device, the compound generating acid upon exposure and acts as a quenching base that neutralizes acid in an unexposed state and being represented by Formula 1: ##STR00001## wherein, in Formula 1, R.sup.a is a C5 to C40 substituted or unsubstituted cyclic hydrocarbon group including at least one nitrogen atom, Y.sup.a is a C1 to C20 divalent linear or cyclic hydrocarbon group, n is an integer of 1 to 5, and A.sup.+ is a counter ion.